司妥昔单抗中国专家推荐临床应用指导原则(2024年版)  

Guidelines for clinical practice of siltuximab by Chinese expert(2024 version)

作　　者：中国临床肿瘤学会(CSCO)淋巴瘤专家委员会 马军[2] 赵东陆[3] 张路[4] 张弦 Lymphoma Expert Committee of Chinese Society of Clinical Oncology(CSCO);Ma Jun(不详;Harbin Institute of Hematology&Oncology,Harbin 150010,China)

机构地区：[1]不详 [2]哈尔滨血液病肿瘤研究所,哈尔滨150010 [3]哈尔滨血液病肿瘤研究所 [4]北京协和医院 [5]河北燕达陆道培医院

出　　处：《白血病．淋巴瘤》2024年第8期449-455,共7页Journal of Leukemia & Lymphoma

摘　　要：司妥昔单抗是一种抗白细胞介素6(IL-6)的单克隆抗体, 可通过靶向中和致IL-6失活, 从而有效治疗特发性多中心型Castleman病。司妥昔单抗在我国于2021年获批, 并于2023年被纳入国家医保目录(2024年1月1日起执行)。多项研究显示, 司妥昔单抗在细胞因子释放综合征等疾病治疗领域也有一定的临床价值。鉴于目前我国临床医师对司妥昔单抗的用药经验有限, 专家组成员参考国内外相关研究进展并结合我国临床实践, 讨论制定了司妥昔单抗临床应用指导原则, 旨在为我国医师临床用药提供参考。Siltuximab is an anti-interleukin-6(IL-6)monoclonal antibody that can target and neutralize human IL-6,leading to its inactivation and effective treatment of idiopathic multicentric Castleman disease.Siltuximab was approved in China in 2021 and was included in the National Reimbursement Drug List in 2023,taking effect on January 1,2024.At the same time,several studies have reported the clinical values of siltuximab in cytokine release syndrome and other diseases.Considering the limited experience of clinicians in China with siltuximab,the members of the expert group discussed and formulated the guidelines for clinical practice of siltuximab by referring to relevant domestic and international researches and combining with clinical practice,in order to provide guidance for Chinese clinicians in clinical drug use.

关 键 词：CASTLEMAN病 司妥昔单抗 白细胞介素6 细胞因子释放综合征 免疫效应细胞相关神经毒性综合征 新型冠状病毒感染 

分 类 号：R978.7[医药卫生—药品]